"It's frankly scary what people will put up with when they're losing weight" Dr Michael Crotty on the rollout of Mounjaro ...

EGOT winner Whoopi Goldberg railed against an ad that's circulating on social media with a manipulated version of her ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

With social media's history of hyped-up health trends, does a 'Mounjaro drink' drink deliver results - or is it just another internet myth? From 'sleepy girl cocktails' to 'oatzempic' drinks there ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

A woman has confessed to no longer fancying her husband, whom she met at university, after she slimmed down to a size 12 on the weight loss jab, while he has now tipped the scales at 20 stone ...

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

Diabetes drug Mounjaro and weight-loss/diabetes medicine ... Adjusted fourth-quarter profit of $5.32 a share topped the analyst estimate of $5.01 per share. During the quarter, Lilly said it ...

GLP-1 drugs Mounjaro and Zepbound drive a big revenue ... The drugmaker's stock (LLY) rose 0.5% in regular trading on Thursday after the company said it expects to generate an adjusted 2025 ...

Eli Lilly's Q4 revenue rose 45% YoY to $13.53B, driven by Mounjaro and Zepbound. Adjusted EPS hit $5.32, beating the $4.94 consensus. 2025 guidance projects $58B-$61B in sales, with a 32% growth ...